Rehm, Martin
Jaensch, Andrea
Schöttker, Ben
Mons, Ute
Hahmann, Harry
Koenig, Wolfgang
Brenner, Hermann
Rothenbacher, Dietrich
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01GD9820/0)
Pitzer Foundation
Waldburg-Zeil Clinics
Universität Ulm
Article History
Received: 2 June 2023
Accepted: 23 August 2023
First Online: 29 August 2023
Declarations
:
: The KAROLA-I study was approved by the ethics committees of the Universities of Ulm (no. 186/98) and Heidelberg and by the medical associations of the states of Baden-Wuerttemberg and Hesse. The KAROLA-II study was approved by the ethics committee of the University of Heidelberg (no. 351/2001). These studies were carried out in accordance with the Declaration of Helsinki, and all methods were used in accordance with the relevant guidelines and regulations. All patients provided written informed consent.
: Not applicable.
: Wolfgang Koenig reports consulting fees from AstraZeneca, Novartis, Pfizer, The Medicines Company, DalCor Pharmaceuticals, Kowa, Amgen, Corvidia Therapeutics, Daiichi-Sankyo, Genentech, Novo Nordisk, Esperion, OMEICOS, LIB Therapeutics, NewAmsterdam Pharma, TenSixteen Bio; speaker honoraria from Amgen, Novartis, Berlin-Chemie, Sanofi, and Bristol-Myers Squibb, grants and non-financial support from Abbott, Roche Diagnostics, Beckmann, and Singulex, outside the submitted work. The other authors have no competing interests to declare that are relevant to the content of this article. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.